Real world data of combined lung cancer and interstitial lung disease

被引：10
|
作者：
Kawahara, Tatsuo [1 ]
Sakashita, Hiroyuki [1 ,2 ]
Suzuki, Takafumi [1 ]
Tateishi, Tomoya [1 ]
Miyazaki, Yasunari [1 ]
机构：
[1] Tokyo Med & Dent Univ, Dept Resp Med, Tokyo, Japan
[2] Yokosuka Kyosai Hosp, Dept Chemotherapy, Yokosuka, Kanagawa, Japan
来源：
JOURNAL OF THORACIC DISEASE | 2019年 / 11卷 / 10期
关键词：
Lung cancer (LC); interstitial lung disease (ILD); chemotherapy; best supportive care (BSC); IDIOPATHIC PULMONARY-FIBROSIS; ACUTE EXACERBATION; CHEMOTHERAPY; IMPACT; DETERIORATION; RESECTION; EFFICACY;
D O I：
10.21037/jtd.2019.10.01
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Background: Research patients with combined lung cancer (LC) and interstitial lung disease (ILD) is insufficient. The objective of the study was to identify the frequency of such patients and treatments, including best supportive care (BSC), in the real world. Methods: All patients with LC who were admitted to our hospital over a 5-year period from 2013 to 2017 were retrospectively analysed. Results: In this study, 698 patients with LC were enrolled. A total of 148 (21.2%) suffered from LC and ILD. Seventy-one LC-ILD patients received chemotherapy, and 20 LC-ILD patients received BSC only. Eleven BSC patients whom physicians thought could receive therapy declined treatment. The median survival time of patients who received chemotherapy was 14.3 months (95% confidence interval, 8.5-19.4 months). The median survival time of BSC patients who declined treatment was 7.2 months and that was shorter than that of patients who received chemotherapy. Conclusions: This study suggests that patients with combined LC and ILD are common (21.2%) in the real world, and there is the possibility that therapy for LC-ILD patients is beneficial.
引用
收藏
页码：4144 / +
页数：9
相关论文
共 50 条
  • [1] REAL WORLD INTERSTITIAL LUNG DISEASE EXPERIENCE - DATA FROM THE AUSTRALASIAN INTERSTITIAL LUNG DISEASE REGISTRY (AILDR)
    Moore, I
    Wrobel, J.
    Lin, Q.
    Webster, S.
    Jo, H.
    Troy, L.
    Grainge, C.
    Glaspole, I
    Thien, F.
    Kwan, B.
    Jee, A.
    Erskine, O.
    Teoh, A.
    De Boer, S.
    Wilsher, M.
    Gallagher, H.
    Corte, T.
    RESPIROLOGY, 2020, 25 : 198 - 198
  • [2] Real World Interstitial Lung Disease Experience - Data from the Australasian Interstitial Lung Disease Registry (AILDR)
    Moore, I.
    Wrobel, J.
    Lin, Q.
    Webster, S.
    Jo, H.
    Troy, L. K.
    Grainge, C.
    Glaspole, I.
    Thien, F.
    Kwan, B.
    Jee, A. S.
    Erskine, O.
    Teoh, A. K.
    De Boer, S.
    Wilsher, M. L.
    Gallagher, H.
    Corte, T. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [3] PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE IN THE REAL WORLD
    Balzat, L.
    Navaratnam, V
    Godfrey, E.
    Watters, C.
    Reddy, T.
    Bancroft, S.
    Divithotawela, C.
    Godbolt, D.
    Pauli, J.
    Goddard, J.
    Trotter, M.
    Hopkins, P.
    Chambers, D.
    Mackintosh, J.
    RESPIROLOGY, 2021, 26 : 170 - 170
  • [4] Treatment and Prognosis of Patients with Lung Cancer and Combined Interstitial Lung Disease
    Mauclet, Charlotte
    Dupont, Michael V.
    Roelandt, Kerwin
    Regnier, Maxime
    Delos, Monique
    Pirard, Lionel
    Vander Borght, Thierry
    Dahlqvist, Caroline
    Froidure, Antoine
    Rondelet, Benoit
    Vanderick, Jean
    Remouchamps, Vincent
    Duplaquet, Fabrice
    Ocak, Sebahat
    CANCERS, 2023, 15 (15)
  • [5] Closing the Evidence Gap in Interstitial Lung Disease The Promise of Real-World Data
    Farrand, Erica
    Anstrom, Kevin J.
    Bernard, Gordon
    Butte, Atul J.
    Iribarren, Carlos
    Ley, Brett
    Martinez, Fernando J.
    Collard, Harold R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199 (09) : 1061 - 1065
  • [6] Interstitial Lung Disease and Lung Cancer
    Lynch, B.
    Kelly, A.
    Ging, P.
    Ronayne, A.
    Teoh, T.
    De Gascun, C.
    Egan, J.
    Kleinerova, J.
    Hannan, M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 : S265 - S265
  • [7] Differentiating interstitial lung abnormalities and interstitial lung disease in lung cancer screening
    Selvarajah, Brintha
    Bhamani, Amyn
    Azimbagihrad, Mehran
    Ozaltin, Burcu
    Egashira, Ryoko
    Mccabe, John
    Smallcombe, Nicola
    Verghese, Priyam
    Prendecki, Ruth
    Creamer, Andrew
    Dickson, Jennifer L.
    Horst, Carolyn
    Tisi, Sophie
    Hall, Helen
    Khaw, Chuen Ryan
    Mullin, Monica
    Gyertson, Kylie
    Hacker, Anne-Marie
    Farrelly, Laura
    Devaraj, Anand
    Nair, Arjun
    Yuneva, Mariia
    Jenkins, R. Gisli
    Chambers, Rachel C.
    Porter, Joanna C.
    Hackshaw, Allan
    Janes, Sam M.
    Jacob, Joseph
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [8] THE OUTCOME OF LUNG CANCER PATIENTS COMBINED WITH INTERSTITIAL LUNG DISEASE TREATED WITH PALLIATIVE CHEMOTHERAPY
    Choi, M. K.
    Ahn, M. -J.
    Sun, J. -M.
    Ahn, J. -S.
    Park, K.
    ANNALS OF ONCOLOGY, 2013, 24
  • [9] Real-World Clinical Profile and Safety of Nintedanib in Systemic Sclerosis-Associated Interstitial Lung Disease: A Subgroup Analysis of Interstitial Lung Disease Data From an Interstitial Lung Disease (ILD) Specialty Clinic in India
    Behera, Ajoy K.
    Sharma, Pratibha
    Ranganath, T. G.
    Kumar, Vikas
    Pati, Saroj K.
    Sinha, Kulshreshth
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [10] Cancer and interstitial lung disease
    Artinian, V
    Kvale, PA
    CURRENT OPINION IN PULMONARY MEDICINE, 2004, 10 (05) : 425 - 434
12345